Powered by Smartsupp

Isomorphic Labs Raises $5 Billion Series C to Launch AI Drug Candidates Into Clinical Trials



By admin | Nov 17, 2026 | 2 min read


Isomorphic Labs Raises $5 Billion Series C to Launch AI Drug Candidates Into Clinical Trials

Isomorphic Labs, an AI-driven drug-discovery platform spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C funding round as it works toward bringing its drug candidates into clinical trials. Greenoaks and Sequoia Capital co-led the round, with new investor Andreessen Horowitz and others participating. All existing backers also invested, including Alphabet's venture arms GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.

Isomorphic Labs develops an AI drug-design engine powered by a range of simulation AI models that explore different areas of chemistry to help design drugs. Building on DeepMind's breakthrough AlphaFold protein-folding AI model, the company said its program has produced "positive preclinical results" in oncology and immunology. The lab has also secured deals with pharmaceutical giants such as Eli Lilly, Novartis, and Johnson & Johnson.

The new funding follows a $2.1 billion Series B round in May and will support continued development of the drug-design engine as well as expansion into additional types of medicine. This Series C marks Isomorphic's first fundraise since founder and CEO Demis Hassabis stepped down as head of DeepMind to concentrate on drug discovery, a move that also saw him take on a chairman role at DeepMind. Hassabis and then-DeepMind director John Jumper won the Nobel Prize in chemistry for the lab's work on AlphaFold, a system that predicts the 3D structure of proteins using only their genetic sequence.

Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was seeking funding at a $50 billion valuation.




RELATED AI TOOLS CATEGORIES AND TAGS

Comments

Please log in to leave a comment.

No comments yet. Be the first to comment!